Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Adagrasib · Krazati, MRTX-849

Small molecule · Inhibitor of KRAS G12C mutant protein (KRAS) · developed by Bristol

Approved FDA, Dec 2022
1 Registered trials

What is Adagrasib?

Adagrasib is an orally available small molecule that covalently binds the cysteine-12 residue of mutant KRAS G12C, locking the protein in its inactive state and blocking downstream signaling. It is studied in advanced or metastatic solid tumors, and is used in KRAS G12C-mutated non-small cell lung cancer and colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Krazati, MRTX-849
Drug type
Small molecule
Targets
KRAS G12C mutant protein (KRAS)
Mechanism
Inhibitor of KRAS G12C mutant protein (KRAS)
Pathways
KRAS downstream signaling, tumor cell growth and viability
Therapy area
Oncology
Developer
Bristol
In trials of
ZLAB
FDA status
Approved as Krazati (December 12, 2022), NDA216340 · FDA label
UNII
8EOO6HQF8Y

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05263986 Phase 1 Advanced or Metastatic Solid Tumor Unknown ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid Tumor

Other drugs acting on KRAS

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.